Ionis Pharmaceuticals (IONS) Short term Debt (2016 - 2025)
Historic Short term Debt for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $630.9 million.
- Ionis Pharmaceuticals' Short term Debt rose 131882.97% to $630.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.9 million, marking a year-over-year increase of 131882.97%. This contributed to the annual value of $44.3 million for FY2023, which is N/A changed from last year.
- According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Short term Debt is $630.9 million, which was up 131882.97% from $630.1 million recorded in Q2 2025.
- In the past 5 years, Ionis Pharmaceuticals' Short term Debt registered a high of $630.9 million during Q3 2025, and its lowest value of $3.5 million during Q4 2021.
- In the last 5 years, Ionis Pharmaceuticals' Short term Debt had a median value of $44.4 million in 2024 and averaged $126.3 million.
- Within the past 5 years, the most significant YoY rise in Ionis Pharmaceuticals' Short term Debt was 138954.22% (2021), while the steepest drop was 9885.82% (2021).
- Over the past 5 years, Ionis Pharmaceuticals' Short term Debt (Quarter) stood at $3.5 million in 2021, then surged by 40.95% to $5.0 million in 2022, then skyrocketed by 791.99% to $44.3 million in 2023, then rose by 0.3% to $44.5 million in 2024, then surged by 1318.83% to $630.9 million in 2025.
- Its Short term Debt was $630.9 million in Q3 2025, compared to $630.1 million in Q2 2025 and $44.5 million in Q3 2024.